The conversation delves into the limited research surrounding the long-term safety of weight loss drugs like Ozempic, particularly at higher dosages. Concerns are raised about the motivations behind the studies, given that they are funded by the manufacturers, leading to questions about transparency and trustworthiness. Additionally, the discussion highlights the troubling history of price gouging by pharmaceutical companies, emphasizing the need for a critical perspective on their practices.
